GSK and CureVac Restructure Partnership, Focusing on MRNA Vaccine Development
GSK and CureVac Restructure Partnership, Focusing on MRNA Vaccine Development
GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritize investment and focus their respective mRNA development activities.
GSK plc（NYSE: GSK）和 Curerac N.V.（NASDAQ: CVAC）今天宣佈，他們已經重組現有合作關係，並簽署了一項新的許可協議，允許雙方公司優先進行投資，並專注於各自的mRNA開發活動。
Since 2020, GSK and CureVac have worked together to develop mRNA vaccines for infectious diseases. Through this collaboration, GSK and CureVac currently have vaccine candidates for seasonal influenza and COVID-19 in Phase 2 and avian influenza in Phase 1 clinical development. All candidates are based on CureVac's proprietary second-generation mRNA backbone. Data generated to date for these candidate vaccines are promising and demonstrate their potential to be best-in-class new vaccines.
自2020年以來，GSK和CureVac一直在共同開發用於傳染病的mRNA疫苗。通過這種合作方式，GSK和CureVac目前擁有季節性流感和COVID-19的疫苗候選者進入第二階段臨床試驗以及禽流感進入第一階段臨床試驗。所有的候選疫苗都是基於CureVac專有的第二代mRNA骨架製備而成的。至今爲止，這些候選疫苗的數據都很有前途，展示了它們成爲最佳新型疫苗的潛力。
Under the terms of the new agreement, GSK will assume full control of developing and manufacturing these candidate vaccines. GSK will have worldwide rights to commercialise the candidate vaccines. The agreement represents the latest step in GSK's ongoing investment in vaccine platform technologies, matching the best platform to each pathogen to develop best-in-class vaccines. mRNA is an adaptable vaccine technology with demonstrated application in emerging and constantly changing viral pathogens due to its ability to support rapid strain change. GSK continues to develop and optimize its mRNA capabilities through investments and partnerships, including in AI/ML-based sequence optimisation, nanoparticle design and manufacturing.
根據新協議的條件，GSK將完全控制這些候選疫苗的開發和製造。GSK將在全球範圍內享有這些候選疫苗的商業化權利。該協議是GSK在疫苗平台技術方面持續投資的最新一步，將最佳平台與每個病原體匹配以開發最佳的疫苗。mRNA是一種可適應性強的疫苗技術，由於其支持快速株系變化的能力，在新興和不斷變化的病毒病原體的應用得到證明。GSK繼續通過投資和合作關係發展和優化其mRNA能力，包括在基於人工智能/機器學習的序列優化、納米粒子設計和製造方面的投資。
CureVac will receive an upfront payment of €400 million and up to an additional €1.05 billion in development, regulatory and sales milestones and tiered royalties in the high single to low teens range. The new agreement replaces all previous financial considerations from the prior collaboration agreement between GSK and CureVac. CureVac further retains exclusive rights to the additional undisclosed and preclinically validated infectious disease targets from the prior collaboration together with the freedom to independently develop and partner mRNA vaccines in any other infectious disease or other indication. CureVac's ongoing patent litigation against Pfizer/BioNTech is unaffected by the new agreement.
CureVac將獲得4億歐元的預付款，以及高單位到低青少年的分層版稅，在開發、監管和銷售里程碑方面最高可獲得10.5億歐元的額外獎勵。新協議將取代GSK和CureVac之間的先前合作協議中的所有金融條款。CureVac還將保留先前合作中未公開並且已經完成臨床驗證的傳染病靶點的獨家權利以及在任何其他傳染病或其他適應症中獨立開發和合作的mRNA疫苗的自由。CureVac對輝瑞和BioNTech的持續專利訴訟不受新協議的影響。
譯文內容由第三人軟體翻譯。